Bültmann & Gerriets
Translating Regenerative Medicine to the Clinic
von Jeffrey Laurence, Pedro Baptista, Anthony Atala
Verlag: Elsevier Health Sciences
Gebundene Ausgabe
ISBN: 978-0-12-800548-4
Erschienen am 10.12.2015
Sprache: Englisch
Format: 277 mm [H] x 211 mm [B] x 23 mm [T]
Gewicht: 1202 Gramm
Umfang: 354 Seiten

Preis: 125,50 €
keine Versandkosten (Inland)


Jetzt bestellen und voraussichtlich ab dem 10. November in der Buchhandlung abholen.

Der Versand innerhalb der Stadt erfolgt in Regel am gleichen Tag.
Der Versand nach außerhalb dauert mit Post/DHL meistens 1-2 Tage.

125,50 €
merken
zum E-Book (EPUB) 92,95 €
klimaneutral
Der Verlag produziert nach eigener Angabe noch nicht klimaneutral bzw. kompensiert die CO2-Emissionen aus der Produktion nicht. Daher übernehmen wir diese Kompensation durch finanzielle Förderung entsprechender Projekte. Mehr Details finden Sie in unserer Klimabilanz.
Klappentext
Inhaltsverzeichnis

Translating Regenerative Medicine to the Clinic reviews the current methodological tools and experimental approaches used by leading translational researchers, discussing the uses of regenerative medicine for different disease treatment areas, including cardiovascular disease, muscle regeneration, and regeneration of the bone and skin. . Pedagogically, the book concentrates on the latest knowledge, laboratory techniques, and experimental approaches used by translational research leaders in this field. It promotes cross-disciplinary communication between the sub-specialties of medicine, but remains unified in theme by emphasizing recent innovations, critical barriers to progress, the new tools that are being used to overcome them, and specific areas of research that require additional study to advance the field as a whole. Volumes in the series include Translating Gene Therapy to the Clinic, Translating Regenerative Medicine to the Clinic, Translating MicroRNAs to the Clinic, Translating Biomarkers to the Clinic, and Translating Epigenetics to the Clinic.



Introduction: Regenerative Medicine for Cardiovascular Disease-A Good Start
PART I: STEM CELLS: 
Chapter 1: Introduction and Overview of Stem Cells
Chapter 2: Mechanistic Insights from Pathologic Perspective
Chapter 3: Large Animal Models to Study Stem Cell Therapy
Section I. Body's Native Repair Mechanisms
Chapter 4. Evolution of understanding of the mechanisms of repair    
Chapter 5: Impact of Age on Stem Cell Function
Section II: Autologous Bone Marrow
Chapter 6: Bone Marrow Mononuclear Cells
Chapter 7: Chronic Limb Ischemia
Chapter 8: Chronic/Refractory Angina
Chapter 9: Acute Myocardial Infarction
A. European Experience:  Andreas Zeiher
B. US Experience: Jay Traverse
Chapter 10: Chronic Ischemic Heart Failure
Section III:  Autologous Adipose Derived Regenerative Cells
Chapter 11: Adipose Tissue
Section IV: Allogeneic Alternatives to Autologous Bone Marrow
Chapter 12: Overview of MSCs    
Chapter 13: Allogeneic vs Autologous Source: Comparative Effects
Chapter 14: Use of MSCs for AMI
Chapter 15: Combined Cell Strategies
Chapter 16: Heart Failure
Section V: Cardiac Progenitor Cells
Chapter 17:  C-Kit+ cells
Chapter 18:  Cardiospheres
Section VI: Other Allogeneic Sources of Stem Cells
Chapter 19:  Umbilical Cord, Placenta, Endometrium
Section VII. Genetic Engineering/Cell Transformation
Chapter 20:  Genetic Engineering of Fibroblasts to Cardiomyocytes
Chapter 21:  Transformation to inducible Pleuripotent Stem Cells
Chapter 22:  Transformation to MAPC's
Section VIII: METHODS OF DELIVERY: 
Chapter 23.  Transcoronary and Endocardial
Chapter 24.  Retrograde and Epicardial
Part II. TISSUE ENGINEERING:
Chapter 25.  Epicardial Patch
Chapter 26.  Matrix Scaffolds
Chapter 27.  Matrix plus cells
Chapter 28.  Biomaterial
Chapter 29:  Organogenesis
Part III. GENE THERAPY:
Chapter 30:  Pre-clinical Identification of target genes
Chapter 31:  SERCA-2a gene for recovery of inotropic function
Chapter 32:  SDF-1 Gene for Heart Failure Non-Inotropic Mechanisms
Chapter 33:  Gene Therapy for Angiogenesis: Chronic Limb Ischemia
Chapter 34:  Stem Cells Target Gene Transfected Stem Cells
Part IV: FUTURE DIRECTIONS:
Chapter 35:  CCTRN: Past, Present, and Vision for the Future
Chapter 36:  Signature of Responders-lessons from Bio-Repository
Chapter 37:  Adjunctive therapy with LVADs for Recovery
Chapter 38:  Trials in Non-Ischemic Heart Failure 
Chapter 39:  Enhancing Stem Cell Homing for Tissue Repair
Chapter 40:  Stroke: Pre-Clinical and Clinical Trial Data
SUMMARY


andere Formate